Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction

Horng Chyuan Lin, Chun Hua Wang, Cheng Ta Yang, Tung Jung Huang, Chih Teng Yu, Wen Bin Shieh, Han Pin Kuo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Bronchial hyper-responsiveness is a cardinal feature of asthma. To determine whether nasal continuous positive airway pressure (NCPAP) influences airway smooth muscle in response to exogenous stimuli, we examined the effect of NCPAP on aerosolized methacholine-induced bronchoconstriction in 16 stable asthmatic patients. The dose-response curve for each subject was measured by a log transformation and linear regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position). The PD20FEV1 significantly increased in patients receiving 8 cmH2O of NCPAP by one doubling dose compared with that in patients using sham pressure. NCPAP shifted the dose-response curves to be flatter, deviated upwards and to the right. The coefficient a, indicating bronchial reactivity, was significantly lower in patients receiving NCPAP. The coefficient b, indicating the bronchial sensitive threshold, was higher after applying NCPAP. In contrast, coefficients a and b did not change in subjects with sham pressure. NCPAP also significantly enhanced the bronchodilator effect of inhaled salbutamol in response to methacholine-induced bronchoconstriction. In summary, we have shown that NCPAP therapy improves bronchial smooth reactivity with an increase in PD20FEV1 and a reduction in the bronchial reactivity and bronchial sensitivity. Therefore, NCPAP may provide an adjuvant therapy in patients with acute bronchial asthma.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalRespiratory Medicine
Volume89
Issue number2
DOIs
Publication statusPublished - Jan 1 1995
Externally publishedYes

Fingerprint

Continuous Positive Airway Pressure
Bronchoconstriction
Methacholine Chloride
Asthma
Pressure
Albuterol
Bronchodilator Agents
Smooth Muscle
Linear Models
Regression Analysis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction. / Lin, Horng Chyuan; Wang, Chun Hua; Yang, Cheng Ta; Huang, Tung Jung; Yu, Chih Teng; Shieh, Wen Bin; Kuo, Han Pin.

In: Respiratory Medicine, Vol. 89, No. 2, 01.01.1995, p. 121-128.

Research output: Contribution to journalArticle

Lin, Horng Chyuan ; Wang, Chun Hua ; Yang, Cheng Ta ; Huang, Tung Jung ; Yu, Chih Teng ; Shieh, Wen Bin ; Kuo, Han Pin. / Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction. In: Respiratory Medicine. 1995 ; Vol. 89, No. 2. pp. 121-128.
@article{0837417492174c1991be9ea3dfcf8638,
title = "Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction",
abstract = "Bronchial hyper-responsiveness is a cardinal feature of asthma. To determine whether nasal continuous positive airway pressure (NCPAP) influences airway smooth muscle in response to exogenous stimuli, we examined the effect of NCPAP on aerosolized methacholine-induced bronchoconstriction in 16 stable asthmatic patients. The dose-response curve for each subject was measured by a log transformation and linear regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position). The PD20FEV1 significantly increased in patients receiving 8 cmH2O of NCPAP by one doubling dose compared with that in patients using sham pressure. NCPAP shifted the dose-response curves to be flatter, deviated upwards and to the right. The coefficient a, indicating bronchial reactivity, was significantly lower in patients receiving NCPAP. The coefficient b, indicating the bronchial sensitive threshold, was higher after applying NCPAP. In contrast, coefficients a and b did not change in subjects with sham pressure. NCPAP also significantly enhanced the bronchodilator effect of inhaled salbutamol in response to methacholine-induced bronchoconstriction. In summary, we have shown that NCPAP therapy improves bronchial smooth reactivity with an increase in PD20FEV1 and a reduction in the bronchial reactivity and bronchial sensitivity. Therefore, NCPAP may provide an adjuvant therapy in patients with acute bronchial asthma.",
author = "Lin, {Horng Chyuan} and Wang, {Chun Hua} and Yang, {Cheng Ta} and Huang, {Tung Jung} and Yu, {Chih Teng} and Shieh, {Wen Bin} and Kuo, {Han Pin}",
year = "1995",
month = "1",
day = "1",
doi = "10.1016/0954-6111(95)90194-9",
language = "English",
volume = "89",
pages = "121--128",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Effect of nasal continuous positive airway pressure on methacholine-induced bronchoconstriction

AU - Lin, Horng Chyuan

AU - Wang, Chun Hua

AU - Yang, Cheng Ta

AU - Huang, Tung Jung

AU - Yu, Chih Teng

AU - Shieh, Wen Bin

AU - Kuo, Han Pin

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Bronchial hyper-responsiveness is a cardinal feature of asthma. To determine whether nasal continuous positive airway pressure (NCPAP) influences airway smooth muscle in response to exogenous stimuli, we examined the effect of NCPAP on aerosolized methacholine-induced bronchoconstriction in 16 stable asthmatic patients. The dose-response curve for each subject was measured by a log transformation and linear regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position). The PD20FEV1 significantly increased in patients receiving 8 cmH2O of NCPAP by one doubling dose compared with that in patients using sham pressure. NCPAP shifted the dose-response curves to be flatter, deviated upwards and to the right. The coefficient a, indicating bronchial reactivity, was significantly lower in patients receiving NCPAP. The coefficient b, indicating the bronchial sensitive threshold, was higher after applying NCPAP. In contrast, coefficients a and b did not change in subjects with sham pressure. NCPAP also significantly enhanced the bronchodilator effect of inhaled salbutamol in response to methacholine-induced bronchoconstriction. In summary, we have shown that NCPAP therapy improves bronchial smooth reactivity with an increase in PD20FEV1 and a reduction in the bronchial reactivity and bronchial sensitivity. Therefore, NCPAP may provide an adjuvant therapy in patients with acute bronchial asthma.

AB - Bronchial hyper-responsiveness is a cardinal feature of asthma. To determine whether nasal continuous positive airway pressure (NCPAP) influences airway smooth muscle in response to exogenous stimuli, we examined the effect of NCPAP on aerosolized methacholine-induced bronchoconstriction in 16 stable asthmatic patients. The dose-response curve for each subject was measured by a log transformation and linear regression analysis as well as a formula fitted to the data points to obtain values for a (slope) and b (position). The PD20FEV1 significantly increased in patients receiving 8 cmH2O of NCPAP by one doubling dose compared with that in patients using sham pressure. NCPAP shifted the dose-response curves to be flatter, deviated upwards and to the right. The coefficient a, indicating bronchial reactivity, was significantly lower in patients receiving NCPAP. The coefficient b, indicating the bronchial sensitive threshold, was higher after applying NCPAP. In contrast, coefficients a and b did not change in subjects with sham pressure. NCPAP also significantly enhanced the bronchodilator effect of inhaled salbutamol in response to methacholine-induced bronchoconstriction. In summary, we have shown that NCPAP therapy improves bronchial smooth reactivity with an increase in PD20FEV1 and a reduction in the bronchial reactivity and bronchial sensitivity. Therefore, NCPAP may provide an adjuvant therapy in patients with acute bronchial asthma.

UR - http://www.scopus.com/inward/record.url?scp=0028965042&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028965042&partnerID=8YFLogxK

U2 - 10.1016/0954-6111(95)90194-9

DO - 10.1016/0954-6111(95)90194-9

M3 - Article

C2 - 7708996

AN - SCOPUS:0028965042

VL - 89

SP - 121

EP - 128

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 2

ER -